Neuropathy Clinical Trial
Official title:
Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients- A Case Series
| NCT number | NCT02615678 |
| Other study ID # | VINJ007 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | October 2015 |
| Est. completion date | December 2018 |
| Verified date | May 2019 |
| Source | Southern California University of Health Sciences |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The aim of this study is to collect preliminary data on the effectiveness of acupuncture for the treatment of CIPN in breast cancer patients.
| Status | Completed |
| Enrollment | 10 |
| Est. completion date | December 2018 |
| Est. primary completion date | December 2018 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility |
Inclusion criteria: 1. Minimum of 18 years of age 2. Currently receiving neurotoxic chemotherapy 3. Experiencing symptoms of chemotherapy induced neuropathy for at least 1 month 4. Have a minimum score of 3 on the VAS should have a grade II CIPN on NCICTC 5. Willing to sign an informed consent 6. Stable treatment for more than two months before screening - Stable treatment is defined as no change in the type and dose of medications 2 months prior to enrollment. - Once enrolled, the patients will be asked to remain on the same type and dose of the medications for neuropathy Exclusion Criteria: 1. Receiving any treatment to prevent neuropathy 2 weeks prior to the screening 2. Pre-existing peripheral neuropathy due to any other cause than chemotherapy 3. Pre-existing conditions like pregnancy, uncontrolled diabetes, hypertension, cardiovascular disorders, bleeding disorders, depression (BDI > 21) 4. Unwilling to follow the protocol 5. Individuals who are receiving government disability assistance |
| Country | Name | City | State |
|---|---|---|---|
| United States | Southern California University of Health Sciences | Whittier | California |
| Lead Sponsor | Collaborator |
|---|---|
| Southern California University of Health Sciences |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Changes in perceived neuropathy as measured by EORTC CIPN-20 | This is a 20-item self-report multidimensional CIPN specific scale that measures sensory, motor and autonomic symptoms of a 1-4 Likert scale. | At baseline, week 6 (treatment 12) and at week 10 (treatment 16) | |
| Secondary | Changes in perceived neuropathy as measured by Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG) Questionnaire | At baseline, week 6 (treatment 12) and at week 10 (treatment 16) | ||
| Secondary | Changes in perceived neuropathy as measured by Visual Analogue Scale of Pain | At baseline, week 6 (treatment 12) and at week 10 (treatment 16) | ||
| Secondary | Changes in quality of life as measured by EORTC QLQ-30 | At baseline, week 6 (treatment 12) and at week 10 (treatment 16) |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03195868 -
Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy
|
N/A | |
| Not yet recruiting |
NCT05565469 -
Correlation Between Abdominal Wall Stimulation and Neurostimulator Tip Location
|
N/A | |
| Completed |
NCT02309164 -
The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN).
|
N/A | |
| Completed |
NCT00775645 -
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy
|
Phase 3 | |
| Completed |
NCT03624426 -
Detection and Prevention of Nerve Injury in Shoulder Arthroplasty Surgery
|
N/A | |
| Withdrawn |
NCT03436680 -
Home-Based Neurofeedback Program in Treating Participants With Chemotherapy-Induced Peripheral Neuropathy
|
N/A | |
| Completed |
NCT05691738 -
Effects of Modified Otago Exercises in Individuals With Diabetic Neuropathy
|
N/A | |
| Completed |
NCT05095870 -
Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
|
||
| Completed |
NCT02011282 -
Electro-Neuro-Muscular Stimulation in ICU
|
N/A | |
| Recruiting |
NCT01774058 -
The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation
|
Phase 2 | |
| Completed |
NCT01135251 -
Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy
|
Phase 2 | |
| Recruiting |
NCT06324344 -
Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy Induced Peripheral Neuropathy (CIPN)
|
N/A | |
| Recruiting |
NCT04403802 -
Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy
|
N/A | |
| Recruiting |
NCT04579406 -
Perioperative Adverse Cardiovascular Event in Type-2 Diabetic Patients
|
||
| Recruiting |
NCT03881930 -
Balance Rehabilitation With Modified Visual Input in Patients With Neuropathy
|
N/A | |
| Completed |
NCT03909464 -
Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy
|
||
| Completed |
NCT01523132 -
Persistent Pain After Breast Cancer Treatment (PPBCT) - Risk Factors and Pathophysiological Mechanisms
|
N/A | |
| Completed |
NCT02689661 -
Impact of the Metabolic Syndrome on the Incidence of Neuropathy in Obese Subjects
|
||
| Terminated |
NCT00998738 -
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
|
Phase 3 | |
| Withdrawn |
NCT00528593 -
Epoetin Alfa for HIV-Associated Neuropathy Trial
|
Phase 2 |